Cellyan Biotechnology Co., Ltd (HKPD) Stock Forecast & Price Target

Cellyan Biotechnology Co., Ltd (HKPD) has an ST Score of 32.2 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Our ST Score grades it C- (32.2/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B+, Profitability D, Financial Strength B, Momentum F, Growth F.

Cellyan Biotechnology Co., Ltd (HKPD) earns a valuation grade of B+, measured against Medical - Distribution peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Cellyan Biotechnology Co., Ltd (HKPD) earns a growth grade of F, measured against Medical - Distribution peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Cellyan Biotechnology Co., Ltd (HKPD) earns a profitability grade of D, measured against Medical - Distribution peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Cellyan Biotechnology Co., Ltd (HKPD) earns a financial strength grade of B, measured against Medical - Distribution peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

Cellyan Biotechnology Co., Ltd (HKPD) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.